Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Waqoo Inc. (4937.T)
Tokyo, JP
Established in 2005 and headquartered in Tokyo, Japan, Waqoo Inc. is primarily engaged in the formulation, production, and sale of cosmetic goods across the Japanese market. Its extensive lineup, sold under the HADA NATURE brand through its dedicated e-commerce platform, encompasses a variety of skincare items such as moisturizing gels, facial and hot cleansers, whitening serums and washes, general serums, protein-based products, and makeup bases. The company also offers hair care solutions, including shampoos, hair oils and masks, and head spa hair growth treatments. Furthermore, Waqoo Inc. diversifies its business by providing medical support services, particularly advertising, and specialized contract services for regenerative medicine, focusing on the processing of blood-derived and fat-derived stem cells.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.53% | +11.96% | +23.01% | +9.46% | -7.16% | +17.22% | +51.83% | +2.79% | -25.35% | -25.35% | -25.35% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Specialty Retail: +6.4%+0.9% Q1'26: +70.0% (vs Q1'25)
-
EPS growth Specialty Retail: +20.6%+344.7% ★ Q1'26: +1,515.9% (vs Q1'25)
-
FCF margin FCF growth · Specialty Retail: +29.3%-0.2% Q1'26: -7.8% (vs Q1'25)
-
EBIT margin Specialty Retail: +5.4%+8.2% ★ Q1'26: +23.7% (vs Q1'25)
-
ROIC Specialty Retail: +6.5%+6.4% Q1'26: +44.9% (vs Q1'25)
-
Share dilution Specialty Retail: +0.1%+3.4% Q1'26: -1.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Specialty Retail: 0.14×2.46× ★ Q1'26: 0.76× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
|---|---|---|---|---|
| Revenue |
4.68B
est: 4.70B (-0.4%)
|
2.73B
est: 3.35B (-18.5%)
|
1.73B
est: 3.95B (-56.3%)
|
1.94B
est: 4.55B (-57.3%)
|
| EBITDA |
155.30M
est: 273.26M (-43.2%)
|
-11.03M
est: 194.77M (-105.7%)
|
295.03M
est: 229.65M (+28.5%)
|
166.48M
est: 1.32B (-87.4%)
|
| EBIT |
149.30M
est: 150.70M (-0.9%)
|
-17.38M
est: 107.41M (-116.2%)
|
288.92M
est: 126.65M (+128.1%)
|
61.69M
est: 668.26M (-90.8%)
|
| Net Income |
116.12M
est: 179.04M (-35.1%)
|
-57.16M
est: 155.17M (-136.8%)
|
28.36M
est: 202.92M (-86.0%)
|
-17.41M
est: 262.60M (-106.6%)
|
| SGA |
3.62B
est: 3.24B (+11.9%)
|
1.94B
est: 2.31B (-16.1%)
|
1.02B
est: 2.72B (-62.7%)
|
1.38B
est: 3.10B (-55.6%)
|
| EPS |
38.69
est: 49.98 (-22.6%)
|
-19.04
est: 43.32 (-144.0%)
|
9.43
est: 56.64 (-83.4%)
|
-5.03
est: 73.30 (-106.9%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bunpei Samata | President & Representative Director | — | male |
| Hiroki Inoue | Founder & Executive Chairman | — | male |
| Keiichi Nakagami | Senior MD & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4937.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
